Director Kim R. Tsuchimoto of Monopar Therapeutics filed a Form 4 on August 27, 2026, reporting six open-market sales of common stock executed on August 26, 2026, under a pre-established Rule 10b5-1 trading plan.
Shana C. Smith, Senior Executive Vice President and Chief Legal Officer of ScanSource, Inc., filed a statement of changes in beneficial ownership with the SEC on August 27, 2026, disclosing a share withholding transaction that occurred on August 25, 2026.
Director Gregory Austin Ciongoli filed a Form 4 with the SEC on August 27, 2026, disclosing three equity transactions in REGENXBIO Inc. common stock between August 25 and August 27, 2026, along with a stock option grant.
Stephen Jones, Senior Executive Vice President and CFO of ScanSource, Inc. (NASDAQ:SCSC), filed a Form 4 on August 27, 2026, disclosing two transactions in which shares of common stock were withheld to satisfy tax obligations upon the vesting of restricted stock units.
A Form 4 filed on August 27, 2026, discloses that Michael L. Baur, CEO, President, and Board of Directors Chair of ScanSource, Inc. (NASDAQ:SCSC), had shares withheld on August 25 and August 26, 2026, to satisfy tax obligations upon the vesting of restricted stock …
A Form 4 filed on August 27, 2026, disclosed that Olivier Le Peuch, Chief Executive Officer and Director of SLB Limited/NV (NYSE:SLB), sold 5,000 shares of common stock on August 27, 2026, under a pre-established Rule 10b5-1 trading plan.
Patrick Hugh Conway, a director at PACS Group, Inc., filed a statement of changes in beneficial ownership on August 27, 2026, disclosing the sale of 3,497 shares of common stock on August 14, 2026.
A Form 4 filed on August 27, 2026, with the SEC discloses that Mark Hancock, a Director and 10% Owner of PACS Group, Inc. (NYSE:PACS), disposed of 88,000 shares of Common Stock on August 18, 2026, via a gift to a charitable donor-advised fund.
Douglas A. Lange, Vice President of the Water Treatment Group at Hawkins Inc (NASDAQ:HWKN), filed a Form 4 on August 27, 2026, disclosing the open-market purchase of 910 shares of common stock on August 25, 2026.
Director Henry O. Gosebruch filed a Form 4 with the SEC on August 27, 2026, disclosing the acquisition of 6,662 shares of ANI Pharmaceuticals Inc common stock on August 19, 2026, in the form of a restricted stock award at no cost.